Endocannabinoid System in Polycystic Kidney Disease.
2-Arachidonoylglycerol
Anandamide
Autosomal dominant polycystic kidney disease
Endocannabinoids
Journal
American journal of nephrology
ISSN: 1421-9670
Titre abrégé: Am J Nephrol
Pays: Switzerland
ID NLM: 8109361
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
06
2021
accepted:
06
01
2022
pubmed:
10
3
2022
medline:
14
5
2022
entrez:
9
3
2022
Statut:
ppublish
Résumé
Autosomal dominant polycystic kidney disease (ADPKD) is a commonly inherited disorder characterized by renal cyst formation. A major pathological feature of ADPKD is the development of interstitial inflammation. The endocannabinoid (EC) system is present in the kidney and has recently emerged as an important player in inflammation and the pathogenesis of progressive kidney disease. Data on ECs were collected using a validated mass spectrometry assay from a well-characterized cohort of 102 ADPKD patients (at baseline and after 2- and 4 years on standard vs. rigorous blood-pressure control) and compared to 100 healthy subjects. Compared to healthy individuals, we found higher interleukins-6 and -1b as well as reduced plasma levels of anandamide (AEA), 2-arachidonoyl-glycerol (2-AG), and their congeners in ADPKD patients. Baseline AEA concentration negatively associated with the progression of ADPKD as expressed by the yearly percent change in height-corrected total kidney volume and positively with the yearly change in renal function (measured as estimated glomerular filtration rate, ΔeGFR). AEA analog palmitoylethanolamide (PEA) is also associated positively with the yearly change in eGFR. The results of the present study suggest that ADPKD patients present with lower levels of ECs and that reestablishing the normality of the renal EC system via augmentation of AEA, PEA, and 2-AG levels, either through the increase of their synthesis or through a reduction of their degradation, could be beneficial and may present a promising therapeutic target in said patients.
Identifiants
pubmed: 35263737
pii: 000522113
doi: 10.1159/000522113
pmc: PMC9173653
mid: NIHMS1779396
doi:
Substances chimiques
Endocannabinoids
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
264-272Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK114424
Pays : United States
Informations de copyright
© 2022 S. Karger AG, Basel.
Références
Mediators Inflamm. 2014;2014:978678
pubmed: 24803745
Nature. 1999 Jul 29;400(6743):452-7
pubmed: 10440374
Vitam Horm. 2009;81:469-85
pubmed: 19647123
Br J Pharmacol. 2015 Jan;172(1):142-58
pubmed: 25205418
Fundam Clin Pharmacol. 2002 Aug;16(4):297-302
pubmed: 12570018
Front Endocrinol (Lausanne). 2021 Jul 07;12:720734
pubmed: 34305821
Kidney Int. 2013 May;83(5):855-64
pubmed: 23423256
Pharmacol Res. 2016 Nov;113(Pt A):356-363
pubmed: 27633407
J Am Soc Nephrol. 2009 Sep;20(9):1888-93
pubmed: 19696226
J Clin Invest. 1997 Sep 15;100(6):1538-46
pubmed: 9294122
iScience. 2020 Jul 24;23(7):101301
pubmed: 32629422
Immunology. 2015 Mar;144(3):352-364
pubmed: 25585882
EBioMedicine. 2020 Jan;51:102585
pubmed: 31879244
Br J Pharmacol. 2007 Nov;152(5):717-24
pubmed: 17700721
Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:637-659
pubmed: 31580774
N Engl J Med. 2004 Jan 8;350(2):151-64
pubmed: 14711914
Kidney Int. 2018 Aug;94(2):252-258
pubmed: 29706358
Front Pharmacol. 2019 May 09;10:430
pubmed: 31143113
Eur J Pharmacol. 1998 Jul 17;353(1):23-31
pubmed: 9721036
N Engl J Med. 2014 Dec 11;371(24):2255-66
pubmed: 25399733
Front Biosci (Schol Ed). 2016 Jun 01;8(2):264-77
pubmed: 27100705
Curr Neuropharmacol. 2018 Jan 30;16(2):137-150
pubmed: 28440188
Neuropsychopharmacology. 2018 Jan;43(1):52-79
pubmed: 28857069
Nature. 1997 Aug 21;388(6644):773-8
pubmed: 9285589
Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:619-31
pubmed: 12432948
Clin J Am Soc Nephrol. 2015 Sep 4;10(9):1534-41
pubmed: 26224879
Kidney Int. 2018 Dec;94(6):1127-1140
pubmed: 30249452
PLoS One. 2014 Oct 17;9(10):e109842
pubmed: 25330307
Lancet. 2003 Mar 1;361(9359):774-6
pubmed: 12620752
J Am Soc Nephrol. 2011 Oct;22(10):1809-14
pubmed: 21921140
Nat Rev Nephrol. 2015 Sep;11(9):515-34
pubmed: 25870008
Nature. 1993 Sep 2;365(6441):61-5
pubmed: 7689702
Proc Natl Acad Sci U S A. 2017 May 9;114(19):5005-5010
pubmed: 28439004
N Engl J Med. 2014 Dec 11;371(24):2267-76
pubmed: 25399731
Am J Nephrol. 2020;51(2):86-95
pubmed: 31935741
Adv Pharm Bull. 2018 Aug;8(3):479-487
pubmed: 30276145
Anal Bioanal Chem. 2021 May;413(12):3381-3392
pubmed: 33817753
Br J Pharmacol. 2015 Oct;172(19):4615-25
pubmed: 25537261
Am J Physiol Renal Physiol. 2013 Feb 15;304(4):F376-81
pubmed: 23220721
JAMA. 2012 May 9;307(18):1941-51
pubmed: 22570462
J Basic Clin Physiol Pharmacol. 2016 May 1;27(3):267-76
pubmed: 26280171
Chem Biol. 2010 Nov 24;17(11):1256-66
pubmed: 21095576
Adv Med Sci. 2021 Mar;66(1):72-80
pubmed: 33388673
Cell Mol Life Sci. 2016 Dec;73(23):4449-4470
pubmed: 27402121
Nature. 1994 Dec 15;372(6507):686-91
pubmed: 7990962
J Lipid Res. 2014 Jun;55(6):1139-49
pubmed: 24343898
J Endocr Soc. 2019 Aug 05;3(10):1869-1880
pubmed: 31583368
Biochem Mol Biol Int. 1997 Mar;41(3):619-24
pubmed: 9090470
Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5420-8
pubmed: 25422468
Kidney Int. 2015 Jul;88(1):72-84
pubmed: 25760323
Cell Mol Life Sci. 2003 Mar;60(3):607-16
pubmed: 12737320
Nutr Res. 2016 Jul;36(7):658-62
pubmed: 27333956
PLoS One. 2012;7(8):e43525
pubmed: 22916273
Nephrol Dial Transplant. 1997 Jun;12(6):1089-90
pubmed: 9198029
FASEB J. 2017 Feb;31(2):469-481
pubmed: 27623929
Am J Physiol Renal Physiol. 2014 Dec 1;307(11):F1198-206
pubmed: 25234311
J Neuroimmune Pharmacol. 2013 Mar;8(1):323-32
pubmed: 23299999
FASEB J. 2018 Oct;32(10):5716-5723
pubmed: 29879374
Nat Rev Drug Discov. 2018 Sep;17(9):623-639
pubmed: 30116049
Int J Mol Sci. 2020 Apr 16;21(8):
pubmed: 32316328